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Introduction: Risk thresholds for using statins to
prevent cardiovascular disease (CVD) have recently
been lowered, so an increasing number of patients are
now prescribed these drugs. Although the safety of
long-term statin use has been generally established,
concerns about the balance of risks and benefits of
statins still exist for some medical professionals and
patients, and issues concerning their side effects are
occasionally widely publicised. This study will report
the rates of stopping for statins and also identify any
patient groups more likely to stop using statins, so
possibly increasing their risk of cardiovascular events.
Methods and analysis: A prospective open cohort
study between 1 January 2002 and 30 September
2014 will be based on the general population of people
prescribed statins, using records from UK general
practices contributing to the Clinical Practice Research
Database (CPRD). Participants aged 25–84 years will
enter the cohort on the date of their first prescription
for a statin and leave on the earliest date of: a
cardiovascular event; death; leaving the practice; the
last practice upload date or the study end date. If there
are no prescriptions within 90 days after the expected
finishing date of a prescription, a patient will be
defined as a stopper with the discontinuation outcome
date as the expected finishing date. Rates of statin
discontinuation will be calculated by calendar year,
type and dose of statin, age, and morbidities. Cox
proportional regression analyses will be run to identify
the most important factors associated with
discontinuation. Analyses will be run separately for
patients without CVD (primary prevention) and with
diagnosed CVD (secondary prevention).
Ethics and dissemination: The protocol has been
reviewed and approved by Independent Scientific
Advisory Committee for MHRA Database Research.
The results will be published in a peer-reviewed journal.
INTRODUCTION
Cardiovascular disease (CVD), which
includes heart attacks and strokes, has a
major impact on the lives of affected indivi-
duals and treatment costs are a signiﬁcant
burden for health services.1 A high level of
low-density lipoprotein (LDL) cholesterol is
a signiﬁcant risk factor for CVD2 and statins
are frequently prescribed as a preventive
measure to reduce cholesterol levels. In the
UK in 2006, the National Institute for Health
and Care Excellence (NICE) recommended
statins for primary prevention in patients
with a 10-year risk of CVD of 20% or more.3
Subsequently, the Cholesterol Treatment
Trialists meta-analysis (2012),4 which was
based on 27 trials of outcomes for statin
users versus controls, demonstrated in lower
risk patients a risk reduction for major vascu-
lar events of 21% per 1.0 mmol/L from LDL
cholesterol level reduction, and in 2014,
NICE decreased risk threshold for recom-
mending statin prescribing to a 10-year risk
of 10%.5 In the USA, the thresholds for
using statins have also recently been
lowered,6 so many more patients are eligible
to receive prescriptions for these drugs.
The beneﬁts of such preventive therapy
are, however, dependent on the level of
adherence of patients with their prescribed
regime and discontinuation is an extreme
form (zero adherence) of non-adherence.7
In general, non-adherence to prescribed
medication is associated with adverse out-
comes and higher costs of care.8
Discontinuation of statins can cause changes
in platelet activity or inﬂammation, impair
vascular homoeostasis or lead to endothelial
dysfunction and may, therefore, independent
of changes of cholesterol levels, increase risk
Strengths and limitations of this study
▪ Large size and substantial statistical power.
▪ Representative study population.
▪ Uncertainty regarding adherence to statin treat-
ment and exact date of the statin
discontinuation.
▪ Possible underestimation of statin use due to
over-the-counter use.
▪ Lack of information on some factors that might
affect patients’ decisions to stop statins.
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of cardiovascular events.9 A number of studies in
patients with acute cardiovascular conditions have
demonstrated problems associated with statin with-
drawal. In one, hospitalised patients who discontinued
statins were found to have a three times higher rate of
myocardial infarction (HR 2.93, 95% CI 1.64 to 6.27)
than patients who continued to receive statins.10 Other
studies have demonstrated that stopping statins after an
acute cardiovascular event increased mortality risk or
worsened the outcome.11 12 One randomised controlled
trial in patients with stable cardiac conditions found no
signiﬁcant differences in rates of cardiac events or
deaths from heart disease associated with statin discon-
tinuation, but the number of actual events was too low
to allow for the effect of statin non-adherence—24 in
the prior 6-week wash-out period compared with 31 in
the 8-week therapy period.13
However, while statin therapy is associated with
decreased mortality and fewer complications related to
atherosclerosis for patients already diagnosed with CVD,
this has not been established for patients without CVD.
Statins also have side effects and a number of studies
have demonstrated these,14 which include increased
risks for diabetes15 16 and myopathy.17 18 With respect to
their effectiveness in patients without CVD, a
meta-analysis of 11 randomised controlled trials
reported no signiﬁcant associations between statin use
and mortality risk for such patients (risk ratio 0.91, 95%
CI 0.83 to 1.01).19 A later meta-analysis, investigating the
effect of cholesterol-lowering therapy on all-cause mor-
tality, did show a signiﬁcantly reduced risk for patients
without CVD (risk ratio 0.91, 95% CI 0.88 to 0.93).4
However, as highlighted in a subsequent secondary ana-
lysis, this reduced mortality was not demonstrated for
the subgroup with low cardiovascular risk (0.95, 0.86 to
1.04 for CVD risk <10%).20 Moreover, the original
ﬁnding might simply have reﬂected a healthy-user bias
because a study investigating the risk of accidents asso-
ciated with adherence to statins21 has shown adherent
patients to be less likely to be involved in accidents (HR
0.85, 95% CI 0.83 to 0.87) and more likely to use screen-
ing services (1.17, 1.15 to 1.20).
While the safety of long-term statin use has, therefore,
been supported by systematic reviews,4 22 issues about
their side effects, effectiveness and the balance of risks
and beneﬁts, especially for people at low risk of CVD,
have occasionally been widely publicised.20 23 So con-
cerns do still exist among some medical professionals
and their patients, and statin non-adherence and discon-
tinuation seem likely to rise as more low-risk patients are
included, who have no symptoms and might regard such
preventive medications as unimportant or risky.24 25
Non-adherence to drug treatments is, however, a many-
layered issue, which can be related to a poor healthcare
system, the type of condition, patient characteristics, the
complexity or side effects of the therapy, or speciﬁc
socioeconomic issues for a treatment group.8 For statins
in a UK study environment, issues to do with the health
system or cost of treatment are unlikely to be signiﬁcant.
Taking statins by themselves is also not a complex
therapy, although issues arising from polypharmacy or
other patient characteristics might well cause discontinu-
ation. Rates of non-adherence to statins in cardiovascular
patients has, however, been shown to be 26%,26 while a
recent American study has reported that more than 50%
of statin users stopped treatment at least temporarily.27
The proportion of patients who discontinue statins
and their reasons for doing so are not, however, clear.
Discrepancies between randomised controlled trials and
observational studies have been shown in a
meta-analysis,28 which reported for randomised trials a
90.3% (95% CI 89.8% to 90.8%) adherence at 1-year
follow-up against 49% (95% CI 48.9% to 49.2%) for
observational studies. This high adherence found in ran-
domised controlled trials is clearly related to the enrol-
ling of selected populations and provision of a form of
monitoring for the included patients. Observational
studies provide a much closer reﬂection of the real
world, but the very high levels of discontinuations
suggest that many may not be due to statin-related
events, and this has led to a number of studies investigat-
ing patterns of discontinuation and the causes.
Of these, all seem to have concentrated on patients
with already diagnosed CVD, and most were conducted
either before the most recent CVD guidelines were
issued or UK-derived CVD risk estimation was available.
One study, based on Clinical Practice Research Database
(CPRD) data, which showed an association between dis-
continuation and higher total mortality following acute
myocardial infarction,29 has also provided information
about prevalence of comorbidities with respect to differ-
ent patterns of statin use. Another CPRD study has inves-
tigated the factors associated with discontinuation,30 but
this study was conducted in 2002. This assessed discon-
tinuation risks in a mixed group of patients, but having
only 20% of the cohort without diagnosed CVD and fol-
lowing up patients for only 1 year. It has also been noted
that further research is needed particularly for patients
with low cardiovascular risk.31
While there have been observational studies examin-
ing the pattern of uptake of statins32–34 and of unin-
tended effects from statin use,35–37 relatively few studies
have examined the discontinuation of statins. We have,
therefore, designed a study that will follow statin users in
the UK over time, report the rates of stopping for statins
with the discontinuation outcome based on prescription
data, and look at whether these have changed with time
or differ across statin types. The study will also identify
any patient groups more likely to stop statins and so pos-
sibly increase their risk of CVD.
METHODS AND ANALYSIS
Data source
We will use data from 664 UK general practices
contributing to the CPRD (http://www.cprd.com).
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The practices are spread across the UK, and their regis-
tered patients have been shown to be representative of
the general population.38 Data are routinely collected
and the recorded information includes demographics,
patient characteristics, clinical diagnoses, symptoms
and prescribed medications. The database has been
validated using other sources of information in the UK
and has been used for similar studies for statin
discontinuation.29 30
Sample selection
This will be a prospective open cohort study of new
statin users identiﬁed during the study period between 1
January 2002 and 30 September 2013. Incident cases
who discontinued statin therapy will be identiﬁed
during follow-up. Patients will enter the cohort on the
date of their ﬁrst recorded statin prescription within the
study inclusion period. Patients will be followed up until
the earliest of: death; deregistration with the practice;
last upload of computerised data; 1 year from the date
the study inclusion period ended. Patients will be subdi-
vided into two groups evaluated on the date when they
started taking statins: those without CVD records before
the entry date (taking statins for primary prevention);
those with CVD diagnosed at or before entering the
study (taking statins for secondary prevention). Patients
without CVD at the baseline date will be followed up
until the time of a CVD diagnosis if it occurs before the
study exit date.
We expect the rate of discontinuation to be lower in
the secondary prevention group, and this subdivision
will make our results more easily comparable with exist-
ing studies.
Inclusion criteria
Eligible patients will be aged 25–84 years at the study
entry, have at least two prescriptions for a statin in the
study period and have at least 1 year of records prior to
entry—calculated from the later date of: the date of
registering with a general practice or the earliest date
of upload of computerised practice data—and at least
1 year of follow-up—calculated from their ﬁrst statin
prescription in the study period. Patients with one or
more prescriptions for statins in the 12 months prior to
cohort entry will be excluded. Cerivastatin will not be
included in the study because it was withdrawn from
the market in August 2001, but patients with prescrip-
tions for it in the 12 months prior to cohort entry will
be excluded.
Exposure
A number of statin users will have only one prescription
before stopping. Because they did not receive a repeat
prescription, it cannot be certain that these patients
actually ever took statins. So, for the main analysis,
having excluded patients with one prescription, we will
run a sensitivity analysis including all patients with one
or more prescriptions. We will report on the percentage
of patients that had only one prescription and describe
characteristics of this group.
The following statins will be included into the analysis:
atorvastatin, simvastatin, ﬂuvastatin, pravastatin and rosu-
vastatin. As the statin most commonly prescribed in the
overall study period, simvastatin—used by around 70%
of patients—will be used as the reference drug.
Outcome
The outcome will be deﬁned as a discontinuation of
statin use if there are no prescriptions within the 90 days
following the expected ﬁnishing date of a prescription.
The ﬁrst such event will be considered as an outcome,
and further prescriptions will not be used in the analysis
of discontinuation. A 90-day exposure window has been
used in other CPRD studies29 30 because it is the longest
prescription length that can be issued in the UK. The
date of the outcome will be deﬁned as the expected ﬁn-
ishing date of the prescription.
Covariates
To describe the cohort and explore factors associated
with the risk of discontinuation, we will consider the
following covariates in six major groups. First, demo-
graphics will include age (<45; 45–54; 55–64; 65–74;
75–84 years), sex, ethnicity (Caucasian or not recorded,
Indian, Pakistani, Bangladeshi, other Asian, Black
African, Black Caribbean, Chinese, other ethnic group)
and socioeconomic status as measured by the Townsend
deprivation score in quintiles. Second, clinical values
will include smoking status (non-smoker; ex-smoker;
light smoker: <10 cigarettes/day; moderate smoker:
10–19 cigarettes/day; heavy smoker: 20+cigarettes/day;
not recorded), body mass index (BMI) in kg/m2 (<25;
25–29.9; 30–34.9; 35+, not recorded), systolic blood pres-
sure and cholesterol/high-density lipoprotein (HDL)
ratio. Third, chronic diseases will include rheumatoid
arthritis, chronic renal disease, liver disease, atrial ﬁbril-
lation, treated hypertension, cancer, heart failure, dia-
betes and dementia. Fourth, genetic characteristics will
include family history of premature coronary heart
disease and diagnosis of familial hypercholesterolaemia.
Fifth, other medications will include use of aspirin, use
of anticoagulants and—as a proxy for comorbid condi-
tions—the number of different types of medicines
having systemic effect and associated with British
National Formulary39 categories (in each case, at least
one prescription in the last year before the entry date).
Finally, only for patients in the primary prevention
group, their 10-year cardiovascular risk as calculated by
the QRISK2–2014 score (banded <5%; 5–9%; 10–14%;
15–19%; 20–24%; 25%+).
For clinical values, the most recently recorded value
prior to or at the cohort entry will be used. Chronic dis-
eases will be considered if they were recorded at or
before the baseline. For the main analysis, we will use
practice-based Townsend deprivation scores as these are
available for the whole cohort. We will run an additional
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analysis on the subset of practices that have consented to
link their data to Townsend scores at patient level.
Statistical analysis
All analyses will be performed separately for the sub-
groups with and without a diagnosis of CVD at the study
entry date.
The numbers of incident users who stop statins will
be reported and the rate of discontinuation will be
assessed by dividing the number of incident stoppers by
the number of person-years. The rates will be calculated
overall and by calendar year, ethnic group, deprivation
quintile, initial statin type, and baseline risk of CVD
(for primary prevention group). We shall also calculate
the percentages of patients who switch between differ-
ent statins during the study period, considering a
patient as a switcher if their type of statin (ingredient)
changed during their follow-up. For patients in the
primary prevention group who were diagnosed with
CVD after entering the study, we shall report the per-
centages of patients who continued using statins after
the diagnosis.
We shall report general descriptive statistics such as
average duration of statin therapy before discontinu-
ation, proportions of patients who had their last statin
prescription within 6 months, 6 months to 1 year,
1–5 years or more than 5 years after their ﬁrst prescrip-
tion, and graphically summarise the data using
Kaplan-Meier curves. As we expect different rates of dis-
continuation for short-term (less than 12 months
between the ﬁrst and the last prescription) and long-
term (more than 12 months between the ﬁrst and the
last prescriptions) users, we shall calculate rates by term
of use.
For those patients who discontinued statins and for
those who did not, summary statistics will be calculated
for the baseline covariates. We shall report frequencies
and proportions for categorical data, and for continuous
data, suggested bands as well as means (SD), medians
and ranges. We shall also report the type of statin, the
potency, calendar year for the baseline, cumulative dur-
ation of exposure before leaving the cohort (deﬁned as
the time interval between the ﬁrst prescription and
expected end date for the last prescription), and
whether the patient had switched statin type during the
study period. We shall calculate the survival-time func-
tion, report the descriptive statistics such as median dur-
ation, plot Kaplan-Meier curves for the covariates and
compare the survivor functions for the covariates using
the log-rank test.
To explore the risks of statin discontinuation asso-
ciated with the covariates, a Cox regression analysis will
be undertaken. The model will include age, sex, ethnic
group, deprivation quintile, calendar year at the entry
to the cohort, baseline CVD risk and the type of statin
prescribed at the baseline. Practices might differ in
their prescription patterns, so we will account for
clustering by practice. We shall calculate the adjusted
HRs for baseline characteristics listed above: clinical
values; chronic diseases; family history; use of other
medications.
The proportional hazards assumption will be checked
by using a log-log plot of survival for each variable.
Variables which violate the assumption will be included
into the model as a stratiﬁcation factor. If clinically
similar variables or categories (for smoking and ethni-
city) are associated with similar risks, they will be com-
bined. For continuous variables, recorded values will be
used. For non-linear risk associations, fractional polyno-
mials will be used if appropriate.40
As BMI, smoking status, systolic blood pressure and
cholesterol/HDL ratio may be important patient
characteristics but have non-negligible numbers of
missing data, multiple imputation will be used to replace
missing values.41 Five imputed data sets will be created,
using multiple chained equations, and Rubin’s rules will
be used to combine effect estimates and SEs to allow for
uncertainty due to imputing missing values. Calendar
year; statin stopper status; log of survival time; age; years
of records; potentially important characteristics; and
type, dose and cumulative exposure to statins will be
included in the imputation model.42
The main analyses will be run using the multiply
imputed data. The least complete data are expected to
be for cholesterol/HDL ratio, but information about
this test is expected to be important for patient adher-
ence. To ensure the robustness of our ﬁndings, we shall
also run a sensitivity analysis including only patients with
complete data.
Additional analyses
Patients might discontinue statins within the ﬁrst year or
after a longer period. The characteristics of these
patients might differ, so we shall rerun the main analysis
twice, in the ﬁrst censoring all patients who did not dis-
continue before the end of year one, and in the second
removing all patients who did discontinue before the
end of year 1.
Some statin users have discontinuous use, with one or
more restarts against a background of fairly continual
usage. We shall deﬁne a subcohort in the study period
for patients who discontinued statins (the outcome date
in the main analysis will be their new entry date) and
follow them until they have a new statin prescription or
they are censored as described in the Study design
section. We shall describe how many people restarted
statin therapy within the ﬁrst 6 months, 7–12 months
and 12 or more months after their new entry dates using
Kaplan-Meier estimates. We shall report descriptive statis-
tics for the covariates listed above both for stoppers who
restarted and those who did not.
Sensitivity analyses
Apart from the two sensitivity analyses already men-
tioned relating to exposure and missing values, two
others will be included. One will be to facilitate
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comparison with the results of the Zhang et al27 study
for long-term statin discontinuation. In this, we will
deﬁne an outcome as an absence of any statin prescrip-
tions within the 12 months (365 days) following the
expected ﬁnishing date of a prescription. As before, the
expected last date will also be the date of the outcome.
Because of the longer period required for an outcome,
for this analysis, we will remove patients with less than
2 years of follow-up records. The other will be run to
investigate the inﬂuence of possible changes in baseline
variables over the full study period, by rerunning the
analysis with the follow-up period restricted to 5 years.
A 1% level of statistical signiﬁcance will be used to
allow for multiple comparisons. Stata V.13 will be used
for all the analyses.
Sample size calculation
All eligible patients will be used in the analyses, allowing
investigation of different types of statins and facilitating
identiﬁcation of relevant patient characteristics asso-
ciated with discontinuation. This approach is particularly
important for the smaller group of patients already diag-
nosed with CVD at baseline.
About one million patients with at least one prescrip-
tion of statin within the study period are available from
the CPRD. Of these, just over one-third had a statin pre-
scription in the past 12 months before the study entry or
insufﬁcient data for follow-up. Excluding these will leave
about 600 000 patients available for analysis, one-quarter
with CVD at the baseline.
For individual drug exposure, 5362 observations will
be required to detect a HR of 0.9 or 1.1 at a signiﬁcance
level of 1% with 90% power between simvastatin and
other statins. For common drugs such as atorvastatin
and rarer drugs such as pravastatin (around 5% of
exposure) we will have enough observations for all these
drug types for both CVD and non-CVD groups. For rare
drugs, such as rosuvastatin (less than 2% of exposure)
and ﬂuvastatin (less than 1% exposure), 1196 patients
will be required to detect a clinically important HR of
0.8 at a signiﬁcance level of 1% with 90% of power. We
will have enough observations for both the CVD and
non-CVD group for rosuvastatin, but only for the
non-CVD group for ﬂuvastatin.
DISCUSSION
This is an observational study based on routinely col-
lected data from a large primary care research database
and will have the strengths and limitations common to
such studies. The strengths include the representative-
ness of the study population, large size of the sample
and substantial statistical power. Information about dis-
continuation rates is scarce, and no previous study has
described discontinuation rates in the general popula-
tion separately for primary and secondary prevention.
Our paper will also report on a signiﬁcantly longer
follow-up time than previous studies.27 28
The limitations of the study will include potential over-
estimation of statin use. While we have precise dates on
which prescriptions were issued, we do not have detailed
information about whether patients took their pills,
when they started and stopped taking the pills, or
whether they followed the prescribed regime, although
it is likely that most patients with more than one pre-
scription were genuine users.43 There is also a possibility
of underestimation of statin use because simvastatin has
been available over-the-counter since 2004, and some
patients might have obtained it without returning to the
general practitioner for repeat prescriptions. These
would appear as false stoppers, but a Health Survey for
England has shown the proportion of patients using
over-the-counter sources (restricted by license to indivi-
duals with a 10–15% 10-year CVD risk) to be very low at
0.2%.44 Another limitation is the lack of information on
reasons for statin discontinuation, such as side effects or
no further need for the drug. Although some of this
information may be recorded, it is too sparse to be used
in the analysis.
Not all of the possible factors associated with statin dis-
continuation, which have been reported by other
studies, will be available for our analysis. Some of them
might have proxies in the form of a similar association,
for example, the social deprivation category in our study
for levels of education or income. Other factors, such as
the quality of communication between patient and
doctor or the patient’s understanding of information
on statins45 are not recorded in primary care databases
and would be infeasible to include in a large study of
this kind.
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